Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.
about
Milnacipran for pain in fibromyalgia in adultsMilnacipran for neuropathic pain and fibromyalgia in adultsSerotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndromeIs the Efficacy of Milnacipran in Fibromyalgia Predictable? A Data-Mining Analysis of Baseline and Outcome VariablesMultidimensional daily diary of fatigue-fibromyalgia-17 items (MDF-fibro-17): part 2 psychometric evaluation in fibromyalgia patientsComparative efficacy and acceptability of amitriptyline, duloxetine and milnacipran in fibromyalgia syndrome: a systematic review with meta-analysis.Interpreting effect sizes and clinical relevance of pharmacological interventions for fibromyalgia.[Drug therapy of fibromyalgia syndrome. Systematic review, meta-analysis and guideline].Combining opioid and adrenergic mechanisms for chronic pain.OMERACT-based fibromyalgia symptom subgroups: an exploratory cluster analysisAn update on pharmacotherapy for the treatment of fibromyalgia.Efficacy of long-term milnacipran treatment in patients meeting different thresholds of clinically relevant pain relief: subgroup analysis of a randomized, double-blind, placebo-controlled withdrawal study.Pharmacotherapy for fibromyalgia.More ubiquitous effects from non-pharmacologic than from pharmacologic treatments for fibromyalgia syndrome: a meta-analysis examining six core symptoms.Ten sessions of adjunctive left prefrontal rTMS significantly reduces fibromyalgia pain: a randomized, controlled pilot studyDevelopment of responder definitions for fibromyalgia clinical trialsDevelopment and initial validation of a brief self-report measure of cognitive dysfunction in fibromyalgia.Juvenile fibromyalgia: current status of research and future developments.Preliminary experience using milnacipran in patients with juvenile fibromyalgia: lessons from a clinical trial program.Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update.Effect of milnacipran on body weight in patients with fibromyalgiaEffect of Milnacipran on Pain in Patients with Rheumatoid Arthritis with Widespread Pain: A Randomized Blinded Crossover Trial.Measures of fibromyalgia: Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), Multidimensional Fatigue Inventory (MFI-20), Medical Outcomes Study (MOS) Sleep Scale, and Multiple Ability Self-Report Questionnaire (MASQ).Milnacipran combined with pregabalin in fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalinBeyond pain in fibromyalgia: insights into the symptom of fatigue.Continuing efficacy of milnacipran following long-term treatment in fibromyalgia: a randomized trial.Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgiaMilnacipran for fibromyalgia: a useful addition to the treatment armamentarium.Pharmacological treatment of chronic non-cancer pain in pediatric patients.Clinical Experience With Desvenlafaxine in Treatment of Patients With Fibromyalgia Syndrome.Alternatives to Opioids in the Pharmacologic Management of Chronic Pain Syndromes: A Narrative Review of Randomized, Controlled, and Blinded Clinical Trials.The antinociceptive effect of milnacipran in the monosodium iodoacetate model of osteoarthritis pain and its relation to changes in descending inhibition.Safety and efficacy of esreboxetine in patients with fibromyalgia: a fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial.[Fibromyalgia].Update on Treatment Guideline in Fibromyalgia Syndrome with Focus on Pharmacology.A Brief Review of the Pharmacology of Amitriptyline and Clinical Outcomes in Treating Fibromyalgia.Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.Longitudinal stability of fibromyalgia symptom clusters.Comparative efficacy and tolerability of duloxetine, pregabalin, and milnacipran for the treatment of fibromyalgia: a Bayesian network meta-analysis of randomized controlled trials.Milnacipran poorly modulates pain in patients suffering from fibromyalgia: a randomized double-blind controlled study
P2860
Q24186461-A70777F9-5CBF-4D44-BB09-28CA7F042452Q24201093-D343542E-D202-472C-8718-2E0956C553D4Q24201799-D25DD8DB-D2FC-466C-91A8-2B5B8DA4DE99Q30983531-410092A9-BDA4-45B3-BC7F-430EBB0DA749Q33706811-B5E584DB-D6F9-449E-BF78-78DB9C56A0E0Q33747253-31E52CC9-0B51-4CC0-817C-DB709222E94FQ33938142-A5B558A5-5CE3-43D6-BC4A-5484CC52F9B4Q34285830-FF529444-CB79-4A26-948E-8B13C30E271EQ34434307-B77EBAD0-151A-4BAD-9C9C-38D59262161BQ34459831-58975FCD-4C24-4F03-8BF4-FB5B0F122CE7Q34477510-9929EEB6-B771-4A6E-8FA1-90DADA43D677Q34584386-C11AB074-D025-47DB-AB12-1C347372D5FEQ35092347-CEC92673-0145-4F25-8A25-7CEF5491F60EQ35228420-FDF3DA8E-0603-4E86-A0EB-9F6030C95671Q35421916-C68222D2-551C-4A23-86E0-29C77FCDB189Q35656228-C427C495-6A46-4C69-ADC4-C0BA192AE549Q35685090-17B3E242-5BCE-4F80-AB53-AB2F7B0DCAC0Q35751360-DDE4235B-7CEE-4DB0-8E17-A438F77D3E76Q35780920-458C23C8-8DCD-4A05-B1C0-5113A8FC62DEQ36185264-83DBD71C-00DB-4C97-81D0-0EC06EC32C84Q36344060-74C4FBE8-F063-43F6-96D7-01FB19A74D16Q36421939-2DECD118-2BFB-42ED-88E3-09BE350905FCQ36480034-9220A72E-E734-4FE9-86DF-6DE90E85ECB3Q36999721-AEAC63C1-2011-4123-B2D3-F725495780EAQ37690090-BC8D405A-E148-4F5A-8C81-3217DAEB2E1BQ37690346-91EC1B36-EAD7-44F7-87B4-352ACF09E4C0Q37690358-B216179B-B03E-474D-BCC2-2BB1509DD072Q38090730-9FA15062-6570-4A1B-AD1A-85D5B27E588CQ38258949-9B132C6E-84EC-4BA8-9159-893CD3AE3D73Q39800410-ED410C0B-BC48-41F3-BD6E-5FEE83C4704AQ43075748-E12C25EF-5FC6-4CB3-AA25-53879BD76DEEQ43238849-4E7120E1-6E22-464F-9A55-CD171A287306Q48262292-9A5D8847-D691-41D3-AE2F-017E4C373ED5Q50993412-0C4F6D7A-8EF6-4DD4-8F69-BB99F7228494Q51817192-4FD053B1-06E6-4330-B3A0-35C12465DC11Q52641632-0F538E18-DFB5-4E2B-843F-EFFCB9F32CAFQ52681690-634541B7-DAAA-4643-AEC2-E3D5C5CCBADFQ52682704-15036189-4172-4F21-9780-9E024119C419Q54437951-F3EAEC49-5856-4BB4-9C5D-17C303660CDBQ57169906-EBE8D7E7-28FF-44CC-849D-AB71CFEA1364
P2860
Efficacy and safety of milnacipran 100 mg/day in patients with fibromyalgia: results of a randomized, double-blind, placebo-controlled trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Efficacy and safety of milnaci ...... ind, placebo-controlled trial.
@en
Efficacy and safety of milnaci ...... ind, placebo-controlled trial.
@nl
type
label
Efficacy and safety of milnaci ...... ind, placebo-controlled trial.
@en
Efficacy and safety of milnaci ...... ind, placebo-controlled trial.
@nl
prefLabel
Efficacy and safety of milnaci ...... ind, placebo-controlled trial.
@en
Efficacy and safety of milnaci ...... ind, placebo-controlled trial.
@nl
P2093
P356
P1476
Efficacy and safety of milnaci ...... ind, placebo-controlled trial.
@en
P2093
Judy F Gendreau
R Michael Gendreau
Robert H Palmer
P304
P356
10.1002/ART.27559
P577
2010-09-01T00:00:00Z